Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease

被引：0
|
作者：
Yarur, A. [1 ]
Bruss, A. [1 ]
Fox, C. [1 ]
Beniwal-Patel, P. [1 ]
Patel, A. [1 ]
Berens, B. [1 ]
Naik, S. [2 ]
Stein, D. [1 ]
机构：
[1] Med Coll Wisconsin, Gastroenterol & Hepatol, Milwaukee, WI 53226 USA
[2] Prometheus Labs, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP048
引用
下载
收藏
页码：S64 / S65
页数：2
相关论文
共 50 条
  • [41] Long Term Prognosis After Discontinuation of Infliximab in Patients With Inflammatory Bowel Disease in Clinical Remission
    Steenholdt, Casper
    Molazahi, Akbar
    Ainsworth, Mark A.
    Brynskov, Jorn
    Thomsen, Ole
    Seidelin, Jakob B.
    GASTROENTEROLOGY, 2012, 142 (05) : S204 - S204
  • [42] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [43] LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FOLLOWING A SIMPLIFIED PROACTIVE DRUG MONITORING ALGORITHM DURING INDUCTION TREATMENT WITH INFLIXIMAB (IFX)
    Garcia, Karoline S.
    Queiroz, Natalia S.
    Parra, Rogerio S.
    Feres, Omar
    Chebli, Julio
    Chebli, Liliana A.
    Flores, Cristina
    Vieira, Andrea
    Azevedo, Matheus F.
    Carlos, Alexandre S.
    Oba, Jane
    Alves, Olivia D.
    Ceara, Christianne D.
    Sipahi, Aytan M.
    Damiao, Aderson O.
    GASTROENTEROLOGY, 2022, 162 (07) : S1097 - S1097
  • [44] INCREASED DIETARY CARBOHYDRATE IS ASSOCIATED WITH CLINICAL ACTIVITY AND WITH ENDOSCOPIC REMISSION IN INFLAMMATORY BOWEL DISEASE
    Sheasgreen, Christopher
    Mohammadi, Aylia
    Boland, Karen
    Atwal, Simen
    Borowski, Krzysztof
    Stempak, Joanne M.
    Silverberg, Mark S.
    GASTROENTEROLOGY, 2017, 152 (05) : S421 - S421
  • [45] Vedolizumab serum drug levels are not associated with clinical outcomes or markers of disease activity in inflammatory bowel disease
    Shields, S.
    Seenan, J. P.
    Nowell, E.
    Dunlop, A.
    Galloway, P.
    Macdonald, J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S424 - S425
  • [46] VEDOLIZUMAB DRUG LEVELS ARE NOT ASSOCIATED WITH OUTCOMES OR DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE
    Shields, Stephanie
    Seenan, John Paul
    Nowell, Emma
    Dunlop, Allan
    Galloway, Peter
    Macdonald, Jonathan
    GUT, 2021, 70 : A122 - A123
  • [47] Ustekinumab concentrations in induction are associated with mid-term endoscopic outcomes in patients with inflammatory bowel disease
    Serra-Ruiz, X.
    Martinez, E. Cespedes
    Ayala, L. Mayorga
    De-Guise, C. Herrera
    Alonso, V. Robles
    Martinez, Z. Perez
    Oller, E.
    Sainz, N. Borruel
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1619 - I1620
  • [48] Vedolizumab Trough Levels in Inflammatory Bowel Disease: Initial Clinical Experience
    Badr, Al-Bawardy
    Guilherme, Piovezani Ramos
    Loftus, Edward, Jr.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S26 - S26
  • [49] Clinical utility of vedolizumab trough levels in the management of inflammatory bowel disease
    Maillard, Michel H.
    Jelk, Daniele
    Perreau, Matthieu
    Rossel, Jean-Benoit
    Pittet, Valerie
    Michetti, Pierre
    SWISS MEDICAL WEEKLY, 2018, 148 : 6S - 6S
  • [50] Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Di Mario, C.
    Papa, A.
    Gremese, E.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S398 - S398
12345